Replies to post #140288 on Biotech Values

[mcbio]

They can't partner EC20 with MRK because they only partner EC145 with MRK. The rest of their folate receptor pipeline will also depend on this test.

So, ECYT will presumably retain all revenues from EC20 in conjunction with EC145 and hopefully any subsequent drugs.